Judo Bio Reveals Data on Gene Silencing via Receptor-Mediated Oligonucleotide Delivery in the Kidney
Judo Bio, a biotechnology company focused on developing oligonucleotide medicines for kidney delivery, has announced the presentation of preclinical data demonstrating a mechanism for the uptake and trafficking of ligand-siRNA conjugates via megalin receptors. This mechanism enables targeted gene knockdown…